Medical science has never offered greater promise for patients with rare diseases. Yet the economics of developing those treatments can keep that promise out of reach.
A drug that treats millions of patients can generate billions in revenue for its developer. A treatment that saves the lives of a few hundred patients may never recover its development costs.
Today’s science offers extraordinary promise. But today’s economics present extraordinary obstacles.
Bringing a new medicine to market can take more than a decade and cost more than $1 billion. Even after years of research and investment, a drug candidate can fail. And small patient populations also complicate clinical trials and limit the potential return on investment.
For rare diseases these challenges are all too common and heartbreaking.
The FDA estimates that more than 10,000 known rare diseases affect approximately 30 million Americans. Yet only about 5% have an FDA-approved treatment.
These numbers reveal a fundamental challenge: Scientific promise alone cannot bring new medicines to patients. Developers must also attract the investment necessary to turn promising discoveries into effective treatments. Moreover, regulators must reform their frameworks to accommodate the conditions surrounding rare diseases.
Under Secretary Robert F. Kennedy, Jr., the Department of Health and Human Services is tackling these challenges head-on, advancing a series of policies over the past year that reduce regulatory obstacles, strengthen economic incentives, and accelerate rare disease innovation.
Last month the FDA announced its Rare Disease Framework Initiative, an important new step to address these challenges. The Agency aims to tailor development and review expectations to each disease, its patients, and the evidence researchers can realistically collect. FDA also plans to involve patients earlier and improve consistency across review teams.
That consistency matters economically. Clearer expectations help researchers design better studies from the beginning, avoid unnecessary costs along the way, and give investors greater confidence to support promising treatments.
Regulatory clarity can reduce uncertainty, but rare disease developers must also overcome another formidable obstacle: the time and cost of clinical research.
In June 2026, HHS launched Operation TrialBlazer, a comprehensive new initiative to eliminate unnecessary delays in clinical research. As part of this broader effort, FDA subsequently introduced a pilot program allowing selected developers to submit portions of early clinical trial applications as they complete them, rather than waiting to assemble the entire package.
For rare disease developers, time is money. For patients with life-threatening conditions, time can mean the difference between life and death.
Reducing regulatory delays can preserve scarce investment dollars, accelerate clinical research, and bring promising rare disease treatments closer to the patients who desperately need them.
But rare diseases also present another challenge. Some affect so few patients that researchers cannot recruit enough participants for conventional clinical trials. Rigid clinical trial requirements can make promising treatments economically impractical — or impossible to evaluate through conventional studies.
FDA’s Plausible Mechanism Framework, announced in February, addresses this problem for individualized therapies targeting severe genetic conditions. The framework outlines how developers could build an evidence package around a clear understanding of a disease’s underlying cause, a treatment that targets that cause, and clinical evidence demonstrating benefit. As with other drugs, FDA continues to require substantial evidence of effectiveness and evidence of safety for such therapies.
Related FDA draft guidance would also allow developers of genome-editing therapies to draw on applicable scientific knowledge from earlier work rather than repeat every study from scratch.
That approach could have significant economic consequences. By allowing researchers to apply sound scientific knowledge across multiple treatments, FDA could help reduce development costs and make therapies for extremely small patient populations more feasible.
Congress and the President have also collaborated on another initiative this year that will assist the development of rare disease treatments and cures. In February 2026, President Trump signed legislation Congress passed extending the Rare Pediatric Disease Priority Review Voucher program through September 2029.
Under the program, developers of qualifying treatments can earn a voucher, which can be redeemed for faster FDA review of another product or sold to another company. The potential financial value can help attract investment in treatments that might otherwise offer too little commercial return. It could also provide needed financial assistance to rare disease drug developers needing new sources of capital.
For these companies, that incentive can help bridge the gap between the enormous cost of developing a medicine and the limited revenue that a small patient population can generate.
Taken together, these four initiatives address different dimensions of the same fundamental problem: the gap between what medical science can accomplish and what the economics of drug development can sustain.
Clearer regulatory expectations can reduce uncertainty. Faster clinical trial processes can lower costs and preserve time. More flexible scientific approaches can make treatments for very small patient populations feasible. Stronger financial incentives can attract investment where traditional market forces fall short.
For millions of Americans living with rare diseases, the question is no longer simply what science can achieve; it is whether we can create the economic conditions and regulatory reforms that allow those achievements to reach patients. These Trump Administration initiatives move us in that positive direction.
The writer is the Assistant Secretary for Legislation at the U.S. Department of Health and Human Services